Ginkgo Bioworks secured a contract through BARDA’s BioMaP Consortium worth up to $22.2 million to develop cost‑reducing, scalable approaches for domestic monoclonal antibody (mAb) manufacturing focused on anti‑filovirus cocktails discovered at Emory University. Ginkgo will lead a multi‑partner team including Advanced BioScience Laboratories, Isolere Bio, NeuImmune and ProteoNic. The project targets process innovations spanning discovery to downstream production to enable rapid, lower‑cost mAb supply for high‑threat pathogens such as Ebola and Sudan viruses. BARDA framed the award as an investment in national biosecurity and surge manufacturing capacity for therapeutic mAbs. This contract underscores continued government interest in public‑private efforts to strengthen domestic biologics manufacturing for pandemic and biodefense countermeasures.